$793.26 Million in Sales Expected for IDEXX Laboratories, Inc. (NASDAQ:IDXX) This Quarter

Wall Street brokerages expect IDEXX Laboratories, Inc. (NASDAQ:IDXX) to post $793.26 million in sales for the current fiscal quarter, Zacks reports. Four analysts have made estimates for IDEXX Laboratories’ earnings, with the highest sales estimate coming in at $802.30 million and the lowest estimate coming in at $785.50 million. IDEXX Laboratories reported sales of $721.79 million in the same quarter last year, which indicates a positive year-over-year growth rate of 9.9%. The company is scheduled to report its next earnings report on Thursday, November 4th.

According to Zacks, analysts expect that IDEXX Laboratories will report full-year sales of $3.19 billion for the current financial year, with estimates ranging from $3.18 billion to $3.20 billion. For the next fiscal year, analysts expect that the business will post sales of $3.55 billion, with estimates ranging from $3.50 billion to $3.58 billion. Zacks’ sales averages are an average based on a survey of research firms that follow IDEXX Laboratories.

IDEXX Laboratories (NASDAQ:IDXX) last announced its quarterly earnings data on Friday, July 30th. The company reported $2.34 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.01 by $0.33. The company had revenue of $826.14 million during the quarter, compared to analysts’ expectations of $794.64 million. IDEXX Laboratories had a net margin of 23.89% and a return on equity of 115.28%. The business’s revenue was up 29.6% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.72 EPS.

Several research analysts have recently issued reports on the stock. Barclays raised their target price on shares of IDEXX Laboratories from $616.00 to $750.00 and gave the company an “overweight” rating in a research note on Monday, August 2nd. Credit Suisse Group lifted their price objective on shares of IDEXX Laboratories from $735.00 to $770.00 and gave the stock an “outperform” rating in a research note on Friday, August 13th. Guggenheim downgraded shares of IDEXX Laboratories from a “buy” rating to a “neutral” rating in a report on Monday, July 12th. Finally, The Goldman Sachs Group raised their target price on shares of IDEXX Laboratories from $550.00 to $610.00 and gave the stock a “neutral” rating in a report on Tuesday, August 3rd. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average price target of $643.80.

In related news, Director Daniel M. Junius sold 2,402 shares of the company’s stock in a transaction that occurred on Tuesday, August 10th. The stock was sold at an average price of $679.58, for a total value of $1,632,351.16. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Kathy V. Turner sold 276 shares of the stock in a transaction that occurred on Friday, August 27th. The stock was sold at an average price of $678.00, for a total value of $187,128.00. The disclosure for this sale can be found here. In the last three months, insiders have sold 26,886 shares of company stock valued at $18,646,894. Insiders own 2.06% of the company’s stock.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Fifth Third Bancorp increased its position in shares of IDEXX Laboratories by 7.1% during the 1st quarter. Fifth Third Bancorp now owns 10,930 shares of the company’s stock valued at $5,348,000 after purchasing an additional 729 shares during the last quarter. CHICAGO TRUST Co NA purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $1,730,000. HRT Financial LP purchased a new stake in shares of IDEXX Laboratories during the 1st quarter valued at $1,070,000. Aviva PLC increased its position in shares of IDEXX Laboratories by 11.2% during the 2nd quarter. Aviva PLC now owns 34,286 shares of the company’s stock valued at $21,653,000 after purchasing an additional 3,464 shares during the last quarter. Finally, Penobscot Wealth Management purchased a new stake in shares of IDEXX Laboratories during the 2nd quarter valued at $3,069,000. 84.70% of the stock is owned by institutional investors and hedge funds.

NASDAQ:IDXX traded up $3.41 during mid-day trading on Friday, reaching $664.80. 10,219 shares of the company were exchanged, compared to its average volume of 400,608. IDEXX Laboratories has a 12 month low of $347.54 and a 12 month high of $706.95. The company has a fifty day moving average of $677.42 and a 200 day moving average of $589.19. The company has a quick ratio of 1.17, a current ratio of 1.54 and a debt-to-equity ratio of 1.04. The stock has a market cap of $56.56 billion, a PE ratio of 78.83, a PEG ratio of 4.10 and a beta of 0.92.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc engages in the development, manufacture, and distribution of products and services for the animal veterinary, livestock and poultry, dairy and water testing markets. It operates through the following segments: CAG, Water, LPD, and Other. The CAG segment develops, designs, manufactures, and distributes products and performs services for veterinarians and the biomedical analytics market, primarily related to diagnostics and information management.

Further Reading: Stocks Increasing Dividends

Get a free copy of the Zacks research report on IDEXX Laboratories (IDXX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.